Traws Pharma Inc 2026年季度报告

(Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIESEXCHANGE ACT OF 1934 For the quarterly period endedMarch 31, 2026 Or ☐TRANSITION REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIESEXCHANGE ACT OF 1934 Commission file number: 001-36020 Traws Pharma,Inc.(Exact name of registrant as specified in its charter) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant: (1)has filed all reports required to be filed by Section13 or 15(d)of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to filesuch reports), and (2)has been subject to such filing requirements for the past 90 days.⌧Yes☐No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period thatthe registrant was required to submit such files).⌧Yes☐No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company” and “emerging growth company” in Rule12b-2 of the Exchange Act. Large accelerated filer☐Accelerated filer☐Non-accelerated filer☒Smaller reporting company☒Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Act).☐Yes⌧No The number of outstanding shares of the registrant’s Common Stock, par value $0.01 per share, as of May 12, 2026 was15,150,669. TRAWS PHARMA,INC. TABLE OF CONTENTS FOR QUARTERLY REPORT ON FORM10-QFOR THE QUARTER ENDED MARCH 31, 2026 PART I — FINANCIAL INFORMATION Item 1. Financial Statements (Unaudited)3Condensed Consolidated Balance Sheets3Condensed Consolidated Statements of Operations4Condensed Consolidated Statements of Comprehensive (Loss) Income5Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Deficit6Condensed Consolidated Statements of Cash Flows7Notes to Condensed Consolidated Financial Statements8Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations21Item 3. Quantitative and Qualitative Disclosures About Market Risk32Item 4. Controls and Procedures32 PART II — OTHER INFORMATION Item 1. Legal Proceedings32Item 1A. Risk Factors33Item 2. Unregistered Sales of Equity Securities and Use of Proceeds34Item 3. Defaults Upon Senior Securities34Item 4. Mine Safety Disclosures34Item 5. Other Information34Item 6. Exhibits35SIGNATURES36 PARTI — FINANCIAL INFORMATION Traws Pharma,Inc.Condensed Consolidated Balance Sheets(unaudited) Traws Pharma,Inc.Condensed Consolidated Statements of Operations (unaudited) Three Months Ended March31,20262025Revenue$—$57,000Operating expenses:Research and development4,912,0002,506,000General and administrative2,034,0002,754,000Total operating expenses6,946,0005,260,000Loss from operations(6,946,000)(5,203,000)Change in fair value of warrant liability(159,000)26,513,000Other income, net(2,000)180,000Net (loss) income$(7,107,000)$21,490,000Net (loss) income attributable to common stockholders, basic and diluted$(5,692,000)$15,083,000Weighted-average shares of common stock outstanding, basic10,640,6256,965,927Net (loss) income per share of common stock, basic$(0.53)$2.17Weighted-average shares of common stock outstanding, diluted10,640,6257,215,125Net (loss) income per share of common stock, diluted$(0.53)$2.09Net (loss) income attributable to Series C Preferred stockholders, basicand diluted$(1,415,000)$6,407,000Weighted-average shares of Series C Preferred outstanding, basic anddiluted6,7377,398Net (loss) income per share of Series C Preferred, basic and diluted$(210.03)$866.04 Traws Pharma,Inc.Condensed Consolidated Statements of Comprehensive (Loss) Income(unaudited) Three Months Ended March31,20262025Net (loss) income$(7,107,000)$ 21,490,000Other comprehensive (loss) incomeForeign currency translation adjustments(8,000)23,000Other comprehensive (loss) income(8,000)23,000Comprehensive (loss) income$(7,115,000)$ 21,513,000 Traws Pharma,Inc.Condensed Consolidated Statements of Cash Flows(unaudited) TRAWS PHARMA, INC. Notes to Condensed and Consolidated Financial Statements 1. Nature of Business The Company TrawsPharma,Inc.(“Traws Pharma”or the“Company”),formerly known as OnconovaTherapeutics, Inc., was incorporated in the State of Delaware on December 22, 1998 and commencedoperations on January 1, 1999. The Company's headquarters are